PKTX Stock Overview
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs).
Notes are coming soon
ProtoKinetix, Incorporated Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.03|
|52 Week High||US$0.083|
|52 Week Low||US$0.018|
|1 Month Change||-9.09%|
|3 Month Change||-15.61%|
|1 Year Change||-55.88%|
|3 Year Change||-83.33%|
|5 Year Change||-53.16%|
|Change since IPO||650.00%|
Recent News & Updates
|PKTX||US Biotechs||US Market|
Return vs Industry: PKTX underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: PKTX underperformed the US Market which returned -9.7% over the past year.
|PKTX Average Weekly Movement||25.3%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: PKTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 25% a week.
Volatility Over Time: PKTX's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company’s AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases.
ProtoKinetix, Incorporated Fundamentals Summary
|PKTX fundamental statistics|
Is PKTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PKTX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0053|
|Net Profit Margin||0.00%|
How did PKTX perform over the long term?See historical performance and comparison